Cited by 1,674Breast Cancer Treatment StudiesEstrogen and related hormone effectsEndometrial and Cervical Cancer Treatments

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F·2010·The Lancet Oncology

DOI 10.1016/s1470-2045(10)70257-6

Open this paper in CoChat — free account

Abstract

Background The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg), both given orally every day for 5 years, as adjuvant treatment for postmenopausal women with early-stage breast cancer. In this analysis, we assess the long-term outcomes after a median follow-up of 120 months.Methods We used a proportional hazards model to assess the primary endpoint of disease-free survival, and the secondary endpoints of time to recurrence, time to distant recurrence, incidence of new contralateral breast cancer, overall survival, and death with or without recurrence in all randomised patients (anastrozole n=3125, tamoxifen n=3116) and hormone-receptor-positive patients (anastrozole n=2618, tamoxifen n=2598). After treatment completion, we continued to collect data on fractures and serious adverse events in a masked fashion (safety population: anastrozole n=3092, tamoxifen n=3094). This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN18233230.Findings Patients were followed up for a median of 120 months (range 0-145); there were 24,522 woman-years of follow-up in the anastrozole group and 23,950 woman-years in the tamoxifen group. In the full study population, there were significant improvements in the anastrozole group compared with the tamoxifen group for disease-free survival (hazard ratio [HR] 0·91, 95% CI 0·83-0·99; p=0·04), time to recurrence (0·84, 0·75-0·93; p=0·001), and time to distant recurrence (0·87, 0·77-0·99; p=0·03). For hormone-receptor-positive patients, the results were also significantly in favour of the anastrozole group for disease-free survival (HR 0·86, 95% CI 0·78-0·95; p=0·003), time to recurrence (0·79, 0·70-0·89; p=0·0002), and time to distant recurrence (0·85, 0·73-0·98; p=0·02). In hormone-receptor-positive patients, absolute differences in time to recurrence between anastrozole and tamoxifen increased over time (2·7% at 5 years and 4·3% at 10 years) and recurrence rates remained significantly lower on anastrozole than tamoxifen after treatment completion (HR 0·81, 95% CI 0·67-0·98; p=0·03), although the carryover benefit was smaller after 8 years. There was weak evidence of fewer deaths after recurrence with anastrozole compared with tamoxifen treatment in the hormone-receptor-positive subgroup (HR 0·87, 95% CI 0·74-1·02; p=0·09), but there was little difference in overall mortality (0·95, 95% CI 0·84-1·06; p=0·4). Fractures were more frequent during active treatment in patients receiving anastrozole than those receiving tamoxifen (451 vs 351; OR 1·33, 95% CI 1·15-1·55; p<0·0001), but were similar in the post-treatment follow-up period (110 vs 112; OR 0·98, 95% CI 0·74-1·30; p=0·9). Treatment-related serious adverse events were less common in the anastrozole group than the tamoxifen group (223 anastrozole vs 369 tamoxifen; OR 0·57, 95% CI 0·48-0·69; p<0·0001), but were similar after treatment completion (66 vs 78; OR 0·84, 95% CI 0·60-1·19; p=0·3). No differences in non-breast cancer causes of death were apparent and the incidence of other cancers was similar between groups (425 vs 431) and continue to be higher with anastrozole for colorectal (66 vs 44) and lung cancer (51 vs 34), and lower for endometrial cancer (six vs 24), melanoma (eight vs 19), and ovarian cancer (17 vs 28). No new safety concerns were reported.Interpretation These data confirm the long-term superior efficacy and safety of anastrozole over tamoxifen as initial adjuvant therapy for postmenopausal women with hormone-sensitive early breast cancer.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(10)70257-6

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(2005) · The Lancet · doi:10.1016/s0140-6736(05)66544-0 · Cited by 7,626
Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Self-citation
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
Baum, M., Budzar, A. U., Cuzick, J. M., Forbes, J., Houghton, J., Klijn, J. G. M., & Sahmoud, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09088-8 · Cited by 1,958
Self-citation
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial
Nabholtz, J., Buzdar, A. U., Pollak, M., Harwin, W. N., Burton, G., Mangalik, A., Steinberg, M., Webster, A., & von Euler, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3758 · Cited by 989
Self-citation
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Williams, N. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 918
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Coombes, R. C., Kilburn, L., Snowdon, C. F., Paridaens, R., Coleman, R., Jones, S., Jassem, J., van de Velde, C., Delozier, T., Álvarez, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60200-1 · Cited by 901
Self-citation

Show all 27 references

Sorted by citations

Items 201–300 of 1,000

Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review
Banning, M. (2011) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2011.01295.x · Cited by 83
Late effects of cancer treatment in breast cancer survivors
Agrawal, S. (2014) · South Asian Journal of Cancer · doi:10.4103/2278-330x.130445 · Cited by 83
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis
Harnan, S., Tappenden, P., Cooper, K. L., Stevens, J., Bessey, A., Rafia, R., Ward, S. E., Wong, R., Stein, R. C., & Brown, J. E. (2019) · Health Technology Assessment · doi:10.3310/hta23300 · Cited by 83
Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
for the International Breast Cancer Study Group and BIG 1-98 Collaborative Group, Regan, M. M., Price, K. N., Giobbie‐Hurder, A., Thurlimann, B. J. K., & Gelber, R. D. (2011) · Breast Cancer Research · doi:10.1186/bcr2837 · Cited by 82
Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
Henry, N. L., Giles, J. T., & Stearns, V. (2008) · PubMed · Cited by 82
Aromatase Inhibitor–Induced Carpal Tunnel Syndrome: Results From the ATAC Trial
Šestak, I., Sapunar, F. J., & Cuzick, J. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.0236 · Cited by 81
Self-citation
MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1
Hulin, J.-A., Tommasi, S., Elliot, D. J., Hu, D. G., Lewis, B. C., & Mangoni, A. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-14454-1 · Cited by 79
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole
Kamdem, L. K., Liu, Y., Stearns, V., Kadlubar, S. A., Ramı́rez, J., Jeter, S. C., Shahverdi, K., Ward, B. A., Ogburn, E. T., Ratain, M. J., et al. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03791.x · Cited by 81
Harms from breast cancer screening outweigh benefits if death caused by treatment is included
Baum, M. (2013) · BMJ · doi:10.1136/bmj.f385 · Cited by 80
Self-citation
A 2009 Update on the Treatment of Patients with Hormone Receptor—Positive Breast Cancer
Cleator, S. J., Ahamed, E., Coombes, R. C., & Palmieri, C. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.001 · Cited by 82
The risk of contralateral breast cancer: a SEER-based analysis
Giannakeas, V., Lim, D. W., & Narod, S. A. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01417-7 · Cited by 79
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial
Meattini, I., Santis, M. C. D., Visani, L., Scorsetti, M., Fozza, A., Meduri, B., Rose, F. D., Bonzano, E., Prisco, A., Masiello, V., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00661-2 · Cited by 79
Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment
Chargari, C., Kirov, K. M., Bollet, M. A., Magné, N., Védrine, L., Crémades, S., Beuzeboc, P., Fourquet, A., & Kirova, Y. M. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.08.007 · Cited by 79
Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy
Hunt, K. K., Euhus, D., Boughey, J. C., Chagpar, A. B., Feldman, S. M., Hansen, N. M., Kulkarni, S., McCready, D. R., Mamounas, E. P., Wilke, L. G., et al. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5688-z · Cited by 82
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer
Zilli, M., Grassadonia, A., Tinari, N., Giacobbe, A. D., Gildetti, S., Giampietro, J., Natoli, C., & Iacobelli, S. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.08.003 · Cited by 81
The development of endocrine therapy for women with breast cancer
Sainsbury, R. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.07.006 · Cited by 79
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer
Buzdar, A. U. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn739 · Cited by 78
Self-citation
Early and Locally Advanced Breast Cancer: Diagnosis and Treatment National Institute for Health and Clinical Excellence Guideline 2009
Yarnold, J. R. (2009) · Clinical Oncology · doi:10.1016/j.clon.2008.12.008 · Cited by 78
Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease
Eisner, A., & Luoh, S. (2011) · Current Eye Research · doi:10.3109/02713683.2011.594202 · Cited by 79
Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002
Yao, K. A., Winchester, D. J., Czechura, T., & Huo, D. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2745-1 · Cited by 77
Exclusive endocrine therapy or partial breast irradiation for women aged ≥70 years with luminal A-like early stage breast cancer (NCT04134598 – EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures
Meattini, I., Poortmans, P. M., Marrazzo, L., Desideri, I., Brain, E. G. C., Hamaker, M. E., Lambertini, M., Miccinesi, G., Russell, N. S., Saieva, C., et al. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.07.013 · Cited by 76
Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1
Fusi, C., Materazzi, S., Benemei, S., Coppi, E., Trevisan, G., Marone, I. M., Minocci, D., Logu, F. D., Tuccinardi, T., Tommaso, M. R. D., et al. (2014) · Nature Communications · doi:10.1038/ncomms6736 · Cited by 77
Tamoxifen and CYP2D6: A Contradiction of Data
Hertz, D. L., McLeod, H. L., & Irvin, W. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0418 · Cited by 76
Status of adjuvant endocrine therapy for breast cancer
Schiavon, G., & Smith, I. E. (2014) · Breast Cancer Research · doi:10.1186/bcr3636 · Cited by 75
IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer
Sun, X. H., Mao, Y., Wang, J., Zu, L., Hao, M., Cheng, G., Qu, Q., Cui, D., Keller, E. T., Chen, X., et al. (2014) · Oncogene · doi:10.1038/onc.2014.158 · Cited by 75
Retracted
Musculoskeletal Adverse Events Associated with Adjuvant Aromatase Inhibitors
Khan, Q. J., O’Dea, A. P., & Sharma, P. (2010) · Journal of Oncology · doi:10.1155/2010/654348 · Cited by 75
Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer
Mansell, J., Monypenny, I. J., Skene, A. I., Abram, P., Carpenter, R., Gattuso, J., Wilson, C. R., Angerson, W. J., & Doughty, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0291-z · Cited by 75
p53 accumulation is a strong predictor of recurrence in estrogen receptor‐positive breast cancer patients treated with aromatase inhibitors
YAMAMOTO, M., Hosoda, M., Nakano, K., Shusheng, J., Hatanaka, K. C., Takakuwa, E., Hatanaka, Y., Matsuno, Y., & Yamashita, H. (2013) · Cancer Science · doi:10.1111/cas.12302 · Cited by 75
Breast Cancer Survivorship Issues
Stan, D. L., Loprinzi, C. L., & Ruddy, K. J. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.05.005 · Cited by 75
Adjuvant Systemic Therapies in Breast Cancer
Hernandez-Aya, L. F., & Gonzalez-Angulo, A. M. (2013) · Surgical Clinics of North America · doi:10.1016/j.suc.2012.12.002 · Cited by 74
Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2–3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study
Mieog, J. S. D., Morden, J. P., Bliss, J. M., Coombes, R. C., & van de Velde, C. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70328-x · Cited by 74
Aging and osteoporosis in breast and prostate cancer
Vanderwalde, A. M., & Hurria, A. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20103 · Cited by 72
Cost-Effectiveness Analysis of Intraoperative Radiation Therapy for Early-Stage Breast Cancer
Alvarado, M. D., Mohan, A. J., Esserman, L. J., Park, C. C., Harrison, B. L., Howe, R. J., Thorsen, C. M., & Ozanne, E. M. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2997-3 · Cited by 73
The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum
Lønning, P. E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq337 · Cited by 74
Increased fracture rate in women with breast cancer: a review of the hidden risk
Body, J. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-384 · Cited by 72
Synthesis and cytotoxicity of thieno[2,3-b]pyridine and furo[2,3-b]pyridine derivatives
Hung, J. M., Arabshahi, H. J., Leung, E. Y., Reynisson, J., & Barker, D. L. A. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.001 · Cited by 72
Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer
Huiart, L., Dell’Aniello, S., & Suissa, S. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.140 · Cited by 71
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial
Šestak, I., Singh, S., Cuzick, J. M., Blake, G. M., Patel, R., Gossiel, F., Coleman, R., Dowsett, M., Forbes, J., Howell, A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71035-6 · Cited by 70
Self-citation
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer
Naidoo, K., Wai, P. T., Maguire, S. L., Daley, F. M., Haider, S. A., Kriplani, D., Campbell, J., Mirza, H., Grigoriadis, A. E., Tutt, A. N. J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0760 · Cited by 72
Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship
Bodai, B. I., & Nakata, T. E. (2020) · The Permanente Journal · doi:10.7812/tpp/19.129 · Cited by 73
Variation in Anastrozole Metabolism and Pharmacodynamics in Women with Early Breast Cancer
Ingle, J. N., Buzdar, A. U., Schaid, D. J., Goetz, M. P., Batzler, A. J., Robson, M. E., Northfelt, D., Olson, J. E., Perez, E. A., Desta, Z., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3024 · Cited by 70
Self-citation
Black Cohosh and Breast Cancer
Fritz, H., Seely, D., McGowan, J., Skidmore, B., Fernandes, R., Kennedy, D. A., Cooley, K., Wong, R. K. W., Sagar, S. M., Balneaves, L. G., et al. (2013) · Integrative Cancer Therapies · doi:10.1177/1534735413477191 · Cited by 70
Adherence to hormone therapy among women with breast cancer
Brito, C., Portela, M. C., & de Vasconcellos, M. T. L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-397 · Cited by 74
Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer
Gonzalez, T. L., Hancock, M., Sun, S., Gersch, C. L., Larios, J. M., David, W. S., Hu, J., Hayes, D. F., Wang, S., & Rae, J. M. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05564-y · Cited by 70
SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Shomali, M., Cheng, J., Sun, F., Koundinya, M., Guo, Z., Hebert, A. T., McManus, J., Levit, M. N., Hoffmann, D., Courjaud, A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0390 · Cited by 69
Breast cancer incidence and mortality in a transitioning Chinese population: current and future trends
Wong, I. O. L., Schooling, C. M., Cowling, B. J., & Leung, G. M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.532 · Cited by 69
Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: The ‘personalised’ approach?
Brauch, H. B., & Jordan, V. C. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.032 · Cited by 71
Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells
Lui, A. J., New, J., Ogony, J. W., Thomas, S. M., & Lewis-Wambi, J. S. (2016) · BMC Cancer · doi:10.1186/s12885-016-2490-z · Cited by 69
Chemoprevention of Hormone Receptor-Negative Breast Cancer: New Approaches Needed
Uray, I. P., & Brown, P. H. (2010) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-10858-7_13 · Cited by 68
Secondary osteoporosis: Pathophysiology & diagnosis
Emkey, G. R., & Epstein, S. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.07.002 · Cited by 71
Male breast cancer is not congruent with the female disease
Fentiman, I. S. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.02.017 · Cited by 69
Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma
Fujii, R., Hanamura, T., Suzuki, T., Gohno, T., Shibahara, Y., Niwa, T., Yamaguchi, Y., Ohnuki, K., Kakugawa, Y., Hirakawa, H., et al. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.08.019 · Cited by 67
Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
Barton, S. R., Zabaglo, L. A., A’Hern, R., Turner, N. C., Ferguson, T., O'Neill, S., Hills, M., Smith, I., & Dowsett, M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.166 · Cited by 67
Self-citation
Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery
Roukos, D. H. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.5.587 · Cited by 68
Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women
Aydıner, A. (2013) · The Breast · doi:10.1016/j.breast.2013.01.014 · Cited by 66
Mea Culpawith cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine
Roukos, D. H. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.7 · Cited by 66
Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer
Ayres, L. R., Baldoni, A. D. O., Borges, A. P. D. S., & Pereira, L. R. L. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9833-5 · Cited by 65
Progress in endocrine approaches to the treatment and prevention of breast cancer
Obiorah, I. E., & Jordan, V. C. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.09.006 · Cited by 68
Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study
Ramin, C. A., May, B. J., Roden, R. B. S., Orellana, M. M., Hogan, B., McCullough, M. S., Petry, D., Armstrong, D. K., & Visvanathan, K. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1061-4 · Cited by 65
Interpreting the results of noninferiority trials—a review
Cuzick, J. M., & Sasieni, P. D. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01937-w · Cited by 65
Self-citation
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Pinhel, I. F., Hills, M., Drury, S., Salter, J., Sumo, G., A’Hern, R., Bliss, J. M., Šestak, I., Cuzick, J. M., Barrett-Lee, P. J., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3145 · Cited by 67
Self-citation
Review of risk factors for the development of contralateral breast cancer
Lizarraga, I. M., Sugg, S. L., Weigel, R. J., & Scott‐Conner, C. E. H. (2013) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2013.08.002 · Cited by 65
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
Widschwendter, M., Burnell, M., Fraser, L. S. M., Rosenthal, A. N., Philpott, S., Reisel, D., Dubeau, L., Cline, M., Pan, Y., Yi, P.-C., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.08.037 · Cited by 66
Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis
Roberts, K. E., Rickett, K., Greer, R. M., & Woodward, N. E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.010 · Cited by 67
Genomics and Challenges Toward Personalized Breast Cancer Local Control
Roukos, D. H., Lykoudis, E. G., & Liakakos, T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6197 · Cited by 65
Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study
Bartlett, J. M. S., Bloom, K. J., Piper, T., Lawton, T. J., van de Velde, C. J. �., Ross, D. T., Ring, B. Z., Seitz, R. S., Beck, R. A., Hasenburg, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8896 · Cited by 64
Endocrine Therapy in Early Breast Cancer
Krauss, K., & Stickeler, E. (2020) · Breast Care · doi:10.1159/000509362 · Cited by 64
Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer
Yadav, M. R., Barmade, M. A., Tamboli, R. S., & Murumkar, P. R. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.09.038 · Cited by 64
Effects of a Structured Weight-Bearing Exercise Program on Bone Metabolism Among Breast Cancer Survivors: A Feasibility Trial
Peppone, L. J., Mustian, K. M., Janelsins, M. C., Palesh, O. G., Rosier, R. N., Piazza, K. M., Purnell, J. Q., Darling, T. V., & Morrow, G. R. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.030 · Cited by 64
Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors
Mögele, M., Buchholz, S., Seitz, S., & Ortmann, O. (2012) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-011-2181-6 · Cited by 64
The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients
Egeland, N. G., Lunde, S., Jónsdóttir, K., Lende, T. H., Cronin-Fenton, D. P., Gilje, B., Janssen, E. A. M., & Søiland, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161024243 · Cited by 64
Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo – Meta-analyses on efficacy and adverse events based on randomized clinical trials
Rydén, L., Arnlind, M. H., Vitols, S., Höistad, M., & Ahlgren, J. (2016) · The Breast · doi:10.1016/j.breast.2016.01.006 · Cited by 63
Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis
Tseng, O. L.-I., Spinelli, J. J., Gotay, C. C., Ho, W. Y., McBride, M. L., & Dawes, M. G. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x18759291 · Cited by 68
Comparative Effectiveness of Positron Emission Mammography and MRI in the Contralateral Breast of Women With Newly Diagnosed Breast Cancer
Berg, W. A., Madsen, K. S., Schilling, K. J., Tartar, M., Pisano, E. D., Hovanessian‐Larsen, L., Narayanan, D., & Kalinyak, J. E. (2011) · American Journal of Roentgenology · doi:10.2214/ajr.10.6342 · Cited by 63
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
Hadji, P., Ziller, M., Kieback, D., Dornoff, W., Tessen, H. W., Menschik, T., Kuck, J., Melchert, F., & Hasenburg, A. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn762 · Cited by 64
Effect of Endocrine Therapies on Bone in Breast Cancer Patients
Santen, R. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1679 · Cited by 63
Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
Damodaran, S. E., Pradhan, S. C., Umamaheswaran, G., Dharanipragada, K., Reddy, K. S., & Adithan, C. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1891-1 · Cited by 62
Prognostic Value of Lymph Node Micrometastases in Breast Cancer: A Multicenter Cohort Study
Gobardhan, P. D., Elias, S. G., Madsen, E. V. E., van Wely, B., van den Wildenberg, F., Theunissen, E. B. M., Ernst, M. F., Kokke, M. C., van der Pol, C. C., Rinkes, I. H. M. B., et al. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1451-z · Cited by 62
A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative
Brouckaert, O., Paridaens, R., Floris, G., Rakha, E. A., Osborne, C. K., & Neven, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds238 · Cited by 62
Estrogen receptor‐low breast cancer: Biology chaos and treatment paradox
Yu, K., Cai, Y., Wu, S., Shui, R., & Shao, Z.-M. (2021) · 癌症：英文版 · doi:10.1002/cac2.12191 · Cited by 62
The mammary cellular hierarchy and breast cancer
Oakes, S. R., Gallego‐Ortega, D., & Ormandy, C. J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1674-4 · Cited by 66
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
Jackisch, C., Harbeck, N., Huober, J., von Minckwitz, G., Gerber, B., Kreipe, H.-H., Liedtke, C., Marschner, N. W., Möbus, V. J., Scheithauer, H., et al. (2015) · Breast Care · doi:10.1159/000433590 · Cited by 61
Aromatase inhibitors in the breast cancer clinic: focus on exemestane
Asten, K. V., Neven, P., Lintermans, A., Wildiers, H. P. M. W., & Paridaens, R. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0269 · Cited by 64
Cardiotoxicity of systemic agents used in breast cancer
Ades, F., Zardavas, D., Pinto, A. C., Criscitiello, C., Aftimos, P. G., & de Azambuja, E. (2014) · The Breast · doi:10.1016/j.breast.2014.04.002 · Cited by 65
Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer
Bhola, N. E., Jansen, V. M., Bafna, S., Giltnane, J. M., Balko, J. M., Estrada, M. V., Meszoely, I. M., Mayer, I. A., Abramson, V. G., Ye, F., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2475 · Cited by 60
Cardiotoxicity in breast cancer patients treated with radiation therapy: From evidences to controversies
Loap, P., Kirov, K. M., & Kirova, Y. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103121 · Cited by 59
Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: A Pilot Study of the Effects of Vaginal Testosterone Therapy
Feldhaus-Dahir, M., & Travers‐Gustafson, D. (2014) · Sexual Medicine · doi:10.1002/sm2.22 · Cited by 60
Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study
Coleman, R. E., Banks, L. M., Girgis, S. I., Vrdoljak, E., Fox, J. N., Cawthorn, S., Patel, A., Bliss, J. M., Coombes, R. C., & Kilburn, L. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1121-7 · Cited by 59
The sequential use of endocrine treatment for advanced breast cancer: where are we?
Barrios, C. H., Forbes, J., Jonat, W., Conte, P., Gradishar, W. J., Buzdar, A. U., Gelmon, K. A., Gnant, M., Bonneterre, J. M., Toi, M., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr593 · Cited by 59
Self-citation
Adjuvant aromatase inhibitor therapy: Outcomes and safety
Janni, W., & Hepp, P. G. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.12.010 · Cited by 59
Contralateral prophylactic mastectomy: current perspectives
Yao, K. A., Sisco, M., & Bedrosian, I. (2016) · International Journal of Women s Health · doi:10.2147/ijwh.s82816 · Cited by 59
Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis
Akdeniz, D., Schmidt, M. K., Seynaeve, C., McCool, D., Giardiello, D., van den Broek, A. J., Hauptmann, M., Steyerberg, E. W., & Hooning, M. J. (2018) · The Breast · doi:10.1016/j.breast.2018.11.005 · Cited by 57
Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial
Ring, A. E., Šestak, I., Baum, M., Howell, A., Buzdar, A. U., Dowsett, M., Forbes, J., & Cuzick, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5545 · Cited by 58
Self-citation
Genomic Disparities in Breast Cancer among Latinas
Lynce, F. C., Graves, K. D., Jandorf, L. H., Ricker, C. N., Castro, E., Moreno, L., Augusto, B. M., Fejerman, L., & Vadaparampil, S. T. (2016) · Cancer Control · doi:10.1177/107327481602300407 · Cited by 57
Pharmacogenetics of Tamoxifen: Who Should UndergoCYP2D6Genetic Testing?
Higgins, M. J., Rae, J. M., Flockhart, D. A., Hayes, D. F., & Stearns, V. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0014 · Cited by 58
DAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation
Lanzino, M., Maris, P., Sirianni, R., Barone, I., Casaburi, I., Chimento, A., Giordano, C., Morelli, C., Sisci, D., Rizza, P., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.235 · Cited by 57
The treatment of early breast cancer in women over the age of 70
Ring, A. E., Reed, M., Leonard, R. C., Kunkler, I. H., Muss, H. B., Wildiers, H. P. M. W., Fallowfield, L. J., Jones, A. L., & Coleman, R. E. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.234 · Cited by 57
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer
Šestak, I., Harvie, M., Howell, A., Forbes, J., Dowsett, M., & Cuzick, J. M. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2085-6 · Cited by 57
Self-citation
miR-155 and miR-31 are differentially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptor status
Lu, Z.-D., YE, Y., Jiao, D., QIAO, J., Cui, S., & Liu, Z. (2012) · Oncology Letters · doi:10.3892/ol.2012.841 · Cited by 59
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole
Cuzick, J. M. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.9.1377 · Cited by 57
Self-citation

Authors: Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F.
Affiliations: University of London (GB)
Cancer Research UK (GB)
The University of Texas MD Anderson Cancer Center (US)
Royal Marsden Hospital (GB)
University of Newcastle Australia (AU)
Corresponding author: Cuzick, Jack
ORCID: Cuzick, Jack
Baum, Michael
Buzdar, Aman
Howell, Anthony
Dowsett, Mitch
Forbes, John F
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2010-12
Volume: 11
Issue: 12
Pages: 1135-1141
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(10)70257-6
OpenAlex: W2112780046
Cited by: 1,674
References: 27
Citations by year: 2026: 21 · 2025: 35 · 2024: 50 · 2023: 54 · 2022: 63 · 2021: 64 · 2020: 85 · 2019: 66 · 2018: 85 · 2017: 98 · 2016: 101 · 2015: 116 · 2014: 125 · 2013: 148 · 2012: 121
FWCI: 51.63
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Research Explorer (The University of Manchester) (submittedVersion)
NOVA (University of Newcastle Australia) (submittedVersion)
Funders: AstraZeneca
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
Keywords: anastrozole, tamoxifen, adjuvant endocrine therapy, early breast cancer, postmenopausal women, disease-free survival, time to recurrence, distant recurrence, hormone receptor-positive breast cancer, contralateral breast cancer, overall survival, fracture risk, long-term outcomes, ATAC trial, aromatase inhibitors, selective estrogen receptor modulators, breast cancer recurrence
MeSH terms: Anastrozole, Administration, Oral, Breast Neoplasms, Female, Follow-Up Studies, Humans, Neoplasm Staging, Nitriles, Tamoxifen, Triazoles, Treatment Outcome, Chemotherapy, Adjuvant, Postmenopause, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks